Company profile for Nxera Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. The company has built an agile commercial business across Japan and the APAC region, supporting the development and commercialization of innovative therapies. Powered by its proprietary NxWave™ GPCR structure-based drug discovery platform, Nxera Pharma is advancing a str...
Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. The company has built an agile commercial business across Japan and the APAC region, supporting the development and commercialization of innovative therapies. Powered by its proprietary NxWave™ GPCR structure-based drug discovery platform, Nxera Pharma is advancing a strong pipeline both independently and through partnerships with leading pharmaceutical and biotech companies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Japan
Address
Address
Midtown East, 9-7-2 Akasaka Minato-ku. Tokyo 107-0052
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

PEGS Boston Summit

PEGS Boston Summit

Not Confirmed

envelop Contact Supplier

PEGS Boston Summit

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/05/08/3290954/0/en/nxera-files-patent-infringement-action-in-relation-to-its-minig-platform-technology.html

GLOBENEWSWIRE
08 May 2026

https://firstwordpharma.com/story/7259104

FIRSTWORD PHARMA
01 May 2026

https://www.globenewswire.com/news-release/2026/04/15/3274145/0/en/Notice-of-Issuance-of-New-Shares-in-Connection-with-the-Introduction-of-the-Employee-Stock-Ownership-Plan-Matters-Relating-to-Stock-Units-and-Determination-of-Payment-Amount-and-Ot.html

GLOBENEWSWIRE
15 Apr 2026

https://www.globenewswire.com/news-release/2026/04/14/3273091/0/en/Nxera-Pharma-s-QUVIVIQ-daridorexant-25mg-and-50mg-Receives-Approval-in-Taiwan-for-the-Treatment-of-Insomnia.html

GLOBENEWSWIRE
14 Apr 2026

https://www.globenewswire.com/news-release/2026/04/12/3272170/0/en/Nxera-Pharma-s-Partner-Neurocrine-Biosciences-Doses-First-Patient-in-Phase-2-Trial-of-NBI-1117570-for-Adults-with-Schizophrenia.html

GLOBENEWSWIRE
12 Apr 2026

https://www.globenewswire.com/news-release/2026/04/08/3270611/0/en/Nxera-Pharma-Achieves-Second-Development-Milestone-in-Collaboration-with-Eli-Lilly-Targeting-Metabolic-Diseases.html

GLOBENEWSWIRE
08 Apr 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty